Skip to main content

Advertisement

SpringerLink
Log in

Screening for ATM sequence alterations in African-American women diagnosed with breast cancer

  • Preclinical Study/Clinical Trial/Epidmiology/Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background

Women who are heterozygous for variants in the ataxia telangiectasia mutated (ATM) gene, ATM carriers, have been reported to be at increased risk for breast cancer compared with women who do not posses an alteration in this gene. Aside from BRCA1 and BRCA2, there are few data on breast cancer susceptibility genes in African-American women. The goal of this study was to determine whether there is evidence that ATM is a breast cancer susceptibility gene in African-American women.

Methods

One hundred thirty two African-American women were screened for ATM sequence alterations. Thirty-seven (28%) were women with a histological diagnosis of breast cancer (cases). These women were not selected on the basis of a breast cancer family history. Ninety-five (72%) were age-matched women who had not been diagnosed with breast cancer (controls). Genetic variants were identified using denaturing high-performance liquid chromatography (DHPLC).

Results

Twenty-three of the 37 (62%) cases possessed at least one ATM variant. Fifty-eight of the 95 (61%) (P = 0.54) age-matched controls harbored at least one ATM variant. For subjects specifically possessing missense variants, 46% of cases and 48% of controls had these types of sequence variants. In addition, 19% of cases and 34% of controls possessed multiple ATM sequence variants (P = 0.07). The most common polymorphisms were the 378 T→A which was seen in 19% of cases and 27% of controls (P = 0.22), 5557 G→A identified in 22% of cases and 18% of controls (p = 0.40), 2685 A→G which was detected in 11% of cases and 6% of controls (P = 0.22), and 1254 A→G which was found in 3% of cases and 9% of controls (P = 0.36). Hence, there were no significant differences in any of the genetic variants detected between the case and control subjects.

Conclusion

We found no statistically significant differences in the overall frequency of ATM variants, nor any specific variant type or group, between African-American women who had been diagnosed with breast cancer compared with an age-matched cohort of African-American women who did not have breast cancer. ATM, therefore, does not appear to represent a breast cancer susceptibility gene in the general African-American population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Phillips K-A, Glendon G, Knight J (1999) Putting the risk of breast cancer in perspective. N Engl J Med 340:141–144

    Article  PubMed  CAS  Google Scholar 

  2. Thull DL, Vogel VG (2004) Recognition and management of hereditary breast cancer syndromes. Oncologist 9:13–24

    Article  PubMed  Google Scholar 

  3. Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1. BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388

    Article  PubMed  CAS  Google Scholar 

  4. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646

    Article  PubMed  CAS  Google Scholar 

  5. Malone KE, Daling JR, Neal C et al (2000) Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393–1402

    Article  PubMed  CAS  Google Scholar 

  6. Nelen MR Padberg GW, Peeters EA et al (1996) Localization of the gene for Cowden disease to chromosome 10q22–23. Nat Genet 13:114–116

    Article  Google Scholar 

  7. Nelen MR, Padberg GW, Peeters EA et al (2004) CHEK2*1100 delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175–1182

    Article  Google Scholar 

  8. Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100 delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59

    Article  PubMed  CAS  Google Scholar 

  9. McKinnon PJ (2004) ATM and ataxia telangiectasia. EMBO Rep, 5:772–776

    Article  PubMed  CAS  Google Scholar 

  10. Lavin MF (2005) How important is ATM? Radiat Res 163:704

    PubMed  Google Scholar 

  11. Morrell D Cromartie E Swift M (1986) Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 77:89–92

    Google Scholar 

  12. Swift M, Morrell D, Massey PB, Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325:1831–1836

    Article  PubMed  CAS  Google Scholar 

  13. Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3:155–168

    Article  PubMed  CAS  Google Scholar 

  14. De Jong MM, Nolte IM, te Meerman GJ et al (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39:225–242

    Article  PubMed  Google Scholar 

  15. Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF (1999) Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 79:1304–1307

    Article  PubMed  CAS  Google Scholar 

  16. Geoffroy-Perez B, Janin N, Ossian V et al (2001) Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 93:288–293

    Article  PubMed  CAS  Google Scholar 

  17. Olsen JH, Hahnemann JM, Borresen-Dale AL et al (2001) Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 93:121–127

    Article  PubMed  CAS  Google Scholar 

  18. Renwick A, Thompson D, Seal S et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38:873–875

    Article  PubMed  CAS  Google Scholar 

  19. Angele S, Romestaing P, Moullan N et al (2003) ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 63:8717–8725

    PubMed  CAS  Google Scholar 

  20. Szabo CI, Schutte M, Broeks A et al (2004) Are ATM mutations 7271T→G and IVS10-6T→G really high-risk breast cancer-susceptibility alleles? Cancer Res 64:840–843

    Article  PubMed  CAS  Google Scholar 

  21. Thompson D, Duedal S, Kirner J et al (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97:813–822

    Article  PubMed  CAS  Google Scholar 

  22. Stredrick DL, Garcia-Closas M, Pineda MA et al (2006) The ATM missense mutation p.Ser49Cys (c.146C > G) and the risk of breast cancer. Hum Mutat 27:538–544

    Article  PubMed  CAS  Google Scholar 

  23. Heikkinen K, Rapakko K, Karppinen SM et al (2005) Association of common ATM polymorphism with bilateral breast cancer. Int J Cancer 116:69–72

    Article  PubMed  CAS  Google Scholar 

  24. Langholz B, Bernstein JL, Bernstein L et al (2006) On the proposed association of the ATM variants 5557G > A and IVS38–8T > C and bilateral breast cancer. Int J Cancer 119:724–725

    Article  PubMed  CAS  Google Scholar 

  25. Koren M, Kimmel G, Ben-Asher E et al (2006) ATM haplotypes and breast cancer risk in Jewish high-risk women. Br J Cancer 94:1537–1543

    Article  PubMed  CAS  Google Scholar 

  26. Bernstein JL, Bernstein L, Thompson WD et al (2003) ATM variants 7271T > G and IVS10-6T > G among women with unilateral and bilateral breast cancer. Br J Cancer 89:1513–1516

    Article  PubMed  CAS  Google Scholar 

  27. Lindeman GJ, Hiew M, Visvader JE et al (2004) Frequency of the ATM IVS10-6T→G variant in Australian multiple-case breast cancer families. Breast Cancer Res 6:R401–R407

    Article  PubMed  CAS  Google Scholar 

  28. Sommer SS, Buzin CH, Jung M et al (2002) Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet Cytogenet 134:25–32

    Article  PubMed  CAS  Google Scholar 

  29. Sommer SS, Jiang Z, Feng J et al (2003) ATM missense mutations are frequent in patients with breast cancer. Cancer Genet Cytogenet 145:115–120

    Article  PubMed  CAS  Google Scholar 

  30. Bretsky P, Haiman CA, Gilad S et al (2003) The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 12:733–738

    PubMed  CAS  Google Scholar 

  31. Feng J, Yan J, Chen J et al (2003) Absence of somatic ATM missense mutations in 58 mammary carcinomas. Cancer Genet Cytogenet 145:179–182

    Article  PubMed  CAS  Google Scholar 

  32. Thorstenson YR, Roxas A, Kroiss R et al (2003) Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 63:3325–3333

    PubMed  CAS  Google Scholar 

  33. Chenevix-Trench G, Spurdle AB, Gatei M et al (2002) Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 94:205–215

    PubMed  Google Scholar 

  34. Campbell C, Mitui M, Eng L et al (2003) ATM mutations on distinct SNP and STR haplotypes in ataxia-telangiectasia patients of differing ethnicities reveal ancestral founder effects. Hum Mutat 21:80–85

    Article  PubMed  CAS  Google Scholar 

  35. Thompson D, Antoniou AC, Jenkins M et al (2005) Two ATM variants and breast cancer risk. Hum Mutat 25:594–595

    Article  PubMed  Google Scholar 

  36. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics 2000, CA. Cancer J Clin 50:7–33

    CAS  Google Scholar 

  37. Johnson ET (2002) Breast cancer racial differences before age 40–implications for screening. J Natl Med Assoc 94:149–156

    PubMed  Google Scholar 

  38. Pal T, Permuth-Wey J, Holtje T, Sutphen R (2004) BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev 13:1794–1799

    PubMed  CAS  Google Scholar 

  39. Elmore JG, Moceri VM, Carter D, Larson EB (1998) Breast carcinoma tumor characteristics in black and white women. Cancer 83:2509–2515

    Article  PubMed  CAS  Google Scholar 

  40. Mountain JL, Risch N (2004) Assessing genetic contributions to phenotypic differences among ‘racial’ and ‘ethnic’ groups. Nat Genet 36:S48–S53

    Article  PubMed  CAS  Google Scholar 

  41. Royal CD, Dunston GM (2004) Changing the paradigm from ‘race’ to human genome variation. Nat Genet 36:S5–S7

    Article  PubMed  CAS  Google Scholar 

  42. Armstrong K, Micco E, Carney A, Stopfer J, Putt M (2005) Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. Jama 293:1729–1736

    Article  PubMed  CAS  Google Scholar 

  43. Olopade OI, Artioli G (2004) Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 10(1):S5–S9

    Article  PubMed  Google Scholar 

  44. Bernstein JL, Langholz B, Haile RW et al (2004) Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res 6:R199–R214

    Article  PubMed  CAS  Google Scholar 

  45. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS (2002) ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 52:606–613

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Ariel E. Hirsch

    Present address: Department of Radiation Oncology, Massachusetts General Hospital, 88 East Newton Street, EB-11, Boston, MA, 02118, USA

Authors and Affiliations

  1. Department of Radiation Oncology, New York University Medical Center, New York, NY, USA

    Ariel E. Hirsch & Barry S. Rosenstein

  2. Department of Radiation Oncology, Mount Sinai School of Medicine, New York, USA

    David P. Atencio & Barry S. Rosenstein

  3. Department of Dermatology, Mount Sinai School of Medicine, New York, USA

    Barry S. Rosenstein

  4. Department of Community and Preventive Medicine, Mount Sinai School of Medicine, New York, USA

    Barry S. Rosenstein

  5. Department of Radiation Oncology, Boston University Medical Center, 88 East Newton Street, EB-11, Boston, MA, 02118, USA

    Ariel E. Hirsch

Authors
  1. Ariel E. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Atencio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barry S. Rosenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ariel E. Hirsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hirsch, A.E., Atencio, D.P. & Rosenstein, B.S. Screening for ATM sequence alterations in African-American women diagnosed with breast cancer. Breast Cancer Res Treat 107, 139–144 (2008). https://doi.org/10.1007/s10549-007-9531-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9531-x

Keywords

Search

Navigation